# Indivior (INDV) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/INDV
## Company Profile
- Ticker: INDV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom and listed in the U
## Stock Data
- Close: 38.73 USD
- Market cap: 3984676560.35 USD
- Last updated: 2026-08-05
## Business Overview
### Addiction Medicine
Indivior develops and commercializes medicines for substance-use disorders. Its strategy emphasizes long-acting formulations that support sustained treatment while reducing the burden and diversion risks associated with daily medication.
### SUBLOCADE Franchise
SUBLOCADE is a monthly extended-release buprenorphine injection for opioid-use disorder and is the company’s primary commercial product. The formulation is administered by healthcare professionals and provides continuous buprenorphine exposure over the dosing interval.
### Focused Portfolio Strategy
Indivior is concentrating resources on its marketed addiction franchise after deciding not to internally advance INDV-2000 and not to pursue Phase 3 development of INDV-6001. It retains potential U.S. commercial rights to a future viable product developed by the INDV-6001 licensor.
## Why The Stock Is Moving

As of Aug 5, 2026, INDV closed up 6.11% at $38.73. No new same-company headline was identified in the current news window.

## Future Catalysts

- Indivior’s catalysts are Sublocade execution, opioid-use-disorder growth, and any portfolio update that helps the company keep expanding. The company moves on steady commercial execution.

## Recent News
- 2026-08-03 10:31 EST — [Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance](https://biopharmsignal.com/news/INDV/indivior-reports-second-quarter-2026-financial-results-and-raises-full-year-2026-aea080a0) — Source: Indivior
- 2026-07-23 14:00 EST — [Indivior to Report Second Quarter 2026 Financial Results and Host Webcast](https://biopharmsignal.com/news/INDV/indivior-to-report-second-quarter-2026-financial-results-and-host-webcast-e230b5ef) — Source: Indivior
- 2026-05-20 13:00 EST — [New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization](https://biopharmsignal.com/news/INDV/new-studies-show-adherence-to-monthly-injectable-buprenorphine-is-associated-wit-df904f86) — Source: Indivior
- 2026-05-14 11:00 EST — [Indivior to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/INDV/indivior-to-participate-in-upcoming-investor-conferences-1728ace0) — Source: Indivior
- 2026-05-04 11:00 EST — [Indivior Announces $175 Million Accelerated Share Repurchase](https://biopharmsignal.com/news/INDV/indivior-announces-175-million-accelerated-share-repurchase-b248ff09) — Source: Indivior